

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number
WO 02/102836 A2

(51) International Patent Classification⁷: C07K 14/00

(21) International Application Number: PCT/CA02/00911

(22) International Filing Date: 18 June 2002 (18.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/298,403 18 June 2001 (18.06.2001) US
60/330,095 19 October 2001 (19.10.2001) US

(71) Applicant (for all designated States except US): SHIRE
BIOCHEM INC. [CA/CA]; 275 Armand-Frappier Blvd,
Laval, Quebec H7V 4A7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MARTIN, Denis
[CA/CA]; 4728-G rue Gaboury, St-Augustin-de-Des-
maures, Quebec G3A 1E9 (CA). HAMEL, Josée
[CA/CA]; 2401 Maritain, Sillery, Quebec G1T 1N6 (CA).
BRODEUR, Bernard, R. [CA/CA]; 2401 Maritain,
Sillery, Quebec G1T 1N6 (CA). RIOUX, Stéphane
[CA/CA]; 869 avenue des Pinsons, Beauport, Quebec G1E
1J3 (CA). LEBLANC, Geneviève [CA/CA]; 6850 Boul.,
L'Ormiere, Apt. 12, Neufchatel, Quebec G2C 1C1 (CA).
COUTURE, Julie [CA/CA]; 896 C, Jean-Charles Cantin,
St-Augustin-de-Desmaures, Quebec G3A 1A4 (CA).

(74) Agents: MORROW, Joy, D. et al.; Smart & Biggar, P.O.
Box 2999, Station D, 900-55 Metcalfe Street, Ottawa, On-
tario K1P 5Y6 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MORAXELLA (BRANHAMELLA) CATARRHALIS ANTIGENS

(SEQ ID NO: 2)

1 MTAHKDRSTN LSKICLKHCFTTSSLIATLA MGLAMSACSD DRPKSPIIKP
51 ADDGIIILNKD SIMTVKMSKY QPSFAFDGKI IPANQTLNL DTAVIVEHIF
101 VDAGDEVSKG DALLGYFTHL ESLPSEVTTL PAPFDGVVHR VFAHTDQHYD
151 ANTPLIEIHD ISQLKFISYL SSALMNDTKL GDAVTFGVGD IAHVQQISQV
201 NVSEQNPKLI EVHVIIEPNP DEKPKDLLGR RVVGHIDYQG IQVGVMMPSS
251 AVYDSDLNL ALDGFDKPPH KPDAPIDGYV WVVKQDHRLS LSPVKVLEYH
301 PKTQQFLVQG ITEDSLVATV PLPKDAHDKP VKVY*

WO 02/102836 A2

(57) Abstract: The present invention relates to polypeptides of Moraxella (Branhamella) catarrhalis which may be useful for pro-
phylaxis, diagnostic and/or therapy purposes.

MORAXELLA (BRANHAMELLA) CATARRHALIS ANTIGENSFIELD OF THE INVENTION

5 The present invention is related to polypeptides, more particularly polypeptides of Moraxella (Branhamella) catarrhalis which may be used to prevent, diagnose and/or treat Moraxella (Branhamella) catarrhalis infection.

10

BACKGROUND OF THE INVENTION

Moraxella (Branhamella) catarrhalis is a Gram-negative diplococcus that causes respiratory tract infections in humans. M. catarrhalis is now accepted as the third most common cause of 15 otitis media in infants and children, after Streptococcus pneumoniae and Haemophilus influenzae. M. catarrhalis has also been associated with several other types of infection, including sinusitis, persistent cough, acute laryngitis in adults, suppurative keratitis, conjunctivitis neonatorum, and invasive 20 diseases in the immunocompromised host.

Since approximately 90% of M. catarrhalis strains are resistant to antibiotics (β -lactamase positive) and that recurrent otitis media is associated with high morbidity, there is a need for the 25 development of a vaccine that will protect hosts from M. catarrhalis infection. An infection by M. catarrhalis induces an immune response against antigens found at the surface of the bacterial cells. However, many of these surface proteins are still not characterized, nor has the immune response resulting 30 in protection from infection by different strains been determined.

To develop a vaccine that will protect hosts from M. catarrhalis infection, efforts have mainly been concentrated on outer 35 membrane proteins such as the high-molecular-mass protein named ubiquitous surface protein A (UspA). This protein is considered a promising vaccine candidate because a monoclonal antibody and polyclonal antibodies were both shown to be bactericidal and protective in the murine pulmonary-clearance model. However, 40 this protein was shown to be highly variable among the different

strains of M. catarrhalis. In addition to this protein, other M. catarrhalis proteins have generated interest as potential vaccine candidates. The transferrin-binding protein which possesses conserved epitopes exposed on the bacterial surface. 5 However, there was divergence in the degree of antibody cross-reactivity with the protein from one strain to another. Other investigators have also focused on the 45-kDa protein CD (OMP CD). This protein is highly conserved among strains of M. catarrhalis, however adults with chronic obstructive pulmonary 10 disease show variability in the immune response against the OMP CD.

Therefore there remains an unmet need for M. catarrhalis polypeptides which may be used to prevent, diagnose and/or treat 15 Moraxella (Branhamella) catarrhalis infection.

SUMMARY OF THE INVENTION

According to one aspect, the present invention provides an 20 isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID Nos : 2, 4 or fragments or analogs thereof.

According to one aspect, the present invention relates to 25 polypeptides comprising a sequence chosen from SEQ ID No : 2, 4 or fragments or analogs thereof.

In other aspects, there are provided polypeptides encoded by polynucleotides of the invention, pharmaceutical compositions, 30 vectors comprising polynucleotides of the invention operably linked to an expression control region, as well as host cells transfected with said vectors and processes for producing polypeptides comprising culturing said host cells under conditions suitable for expression.

35

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 represents the DNA sequence of BVH-MC6 gene from M. catarrhalis strain ETSU C-2; SEQ ID NO: 1. The underlined

portion of the sequence represents the region coding for the leader peptide.

Figure 2 represents the amino acid sequence of BVH-MC6 5 polypeptide from M. catarrhalis strain ETSU C-2; SEQ ID NO: 2. The underlined sequence represents the 39 amino acid residues leader peptide.

Figure 3 represents the DNA sequence of BVH-MC7 gene from M. catarrhalis strain ETSU C-2; SEQ ID NO: 3. The underlined portion of the sequence represents the region coding for the leader peptide.

Figure 4 represents the amino acid sequence of BVH-MC7 15 polypeptide from M. catarrhalis strain ETSU C-2; SEQ ID NO: 4. The underlined sequence represents the 21 amino acid residues leader peptide.

20 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides purified and isolated polynucleotides, which encode Moraxella polypeptides which may be used to prevent, diagnose and/or treat Moraxella infection.

25 According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof.

30 According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof.

35 According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4.

5

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4.

10

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4.

15

According to one aspect, the present invention relates to polypeptides which comprise an amino acid sequence selected from SEQ ID Nos : 2, 4 or fragments or analogs thereof.

20 According to one aspect, the present invention relates to polypeptides which comprise an amino acid sequence selected from SEQ ID Nos : 2 or 4.

According to one aspect, the present invention relates to 25 polypeptides characterized by the amino acid sequence selected from SEQ ID NO: 2, 4 or fragments or analogs thereof.

According to one aspect, the present invention relates to 30 polypeptides characterized by the amino acid sequence selected from SEQ ID NO: 2 or 4.

According to one aspect, the present invention provides a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or 35 fragments or analogs thereof.

According to one aspect, the present invention provides a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4.

According to one aspect, the present invention relates to epitope bearing portions of a polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof.

5 According to one aspect, the present invention relates to epitope bearing portions of a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4.

According to one aspect, the present invention provides an 10 isolated polynucleotide comprising a polynucleotide chosen from:

- (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2, 4 or fragments or analogs thereof;
- 15 (b) a polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2, 4 or fragments or analogs thereof;
- (c) a polynucleotide encoding a polypeptide having at least 95% 20 identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2, 4 or fragments or analogs thereof;
- (d) a polynucleotide encoding a polypeptide comprising a sequence chosen from: SEQ ID NO: 2, 4 or fragments or 25 analogs thereof;
- (e) a polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide comprising a sequence chosen from: SEQ ID NO: 2, 4 or fragments or analogs thereof;
- 30 (f) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof;
- (g) a polynucleotide comprising a sequence chosen from SEQ ID NO: 1, 3 or fragments or analogs thereof;

(h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).

According to one aspect, the present invention provides an isolated polynucleotide comprising a polynucleotide chosen from:

5 (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;

(b) a polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;

10 (c) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;

(d) a polynucleotide encoding a polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;

15 (e) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;

(f) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;

20 (g) a polynucleotide comprising a sequence chosen from SEQ ID NO: 1 or 3;

(h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).

According to one aspect, the present invention provides an isolated polypeptide comprising a polypeptide chosen from:

30 (a) a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof;

(b) a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof;

- (c) a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof;
- (d) a polypeptide comprising a sequence chosen from SEQ ID NO: 5 2, 4 or fragments or analogs thereof;
- (e) a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof;
- (f) an epitope bearing portion of a polypeptide comprising a 10 sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof;
- (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- (h) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein 15 the secretory amino acid sequence is deleted.

According to one aspect, the present invention provides an isolated polypeptide comprising a polypeptide chosen from:

- (a) a polypeptide having at least 70% identity to a second 20 polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;
- (b) a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;
- (c) a polypeptide having at least 95% identity to a second 25 polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;
- (d) a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;
- (e) a polypeptide capable of raising antibodies having binding 30 specificity for a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;
- (f) an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;

- (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- (h) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the secretory amino acid sequence is deleted.

5

Those skilled in the art will appreciate that the invention includes DNA molecules, i.e. polynucleotides and their complementary sequences that encode analogs such as mutants, variants, homologues and derivatives of such polypeptides, as 10 described herein in the present patent application. The invention also includes RNA molecules corresponding to the DNA molecules of the invention. In addition to the DNA and RNA molecules, the invention includes the corresponding polypeptides and monospecific antibodies that specifically bind to such 15 polypeptides.

In a further embodiment, the polypeptides in accordance with the present invention are antigenic.

20 In a further embodiment, the polypeptides in accordance with the present invention are immunogenic.

In a further embodiment, the polypeptides in accordance with the present invention can elicit an immune response in a host.

25

In a further embodiment, the present invention also relates to polypeptides which are able to generate antibodies having binding specificity to the polypeptides of the present invention as defined above.

30

An antibody that "has binding specificity" is an antibody that recognizes and binds the selected polypeptide but which does not substantially recognize and bind other molecules in a sample, e.g., a biological sample, which naturally includes the selected 35 peptide. Specific binding can be measured using an ELISA assay in which the selected polypeptide is used as an antigen.

In accordance with the present invention, "protection" in the biological studies is defined by a significant increase in the

survival curve, rate or period. Statistical analysis using the Log rank test to compare survival curves, and Fisher exact test to compare survival rates and numbers of days to death, respectively, might be useful to calculate P values and 5 determine whether the difference between the two groups is statistically significant. P values of 0.05 are regarded as not significant.

In an additional aspect of the invention there are provided 10 antigenic/immunogenic fragments of the polypeptides of the invention, or of analogs thereof.

The fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such 15 regions to retain their antigenic/immunogenic properties. Thus, for fragments according to the present invention the degree of identity is perhaps irrelevant, since they may be 100% identical to a particular part of a polypeptide or analog thereof as described herein. The present invention further provides 20 fragments having at least 10 contiguous amino acid residues from the polypeptide sequences of the present invention. In one embodiment, at least 15 contiguous amino acid residues. In one embodiment, at least 20 contiguous amino acid residues.

25 The skilled person will appreciate that analogs of the polypeptides of the invention will also find use in the context of the present invention, i.e. as antigenic/immunogenic material. Thus, for instance proteins or polypeptides which include one or more additions, deletions, substitutions or the 30 like are encompassed by the present invention.

As used herein, "fragments", "analogs" or "derivatives" of the polypeptides of the invention include those polypeptides in which one or more of the amino acid residues are substituted 35 with a conserved or non-conserved amino acid residue (preferably conserved) and which may be natural or unnatural. In one embodiment, derivatives and analogs of polypeptides of the invention will have about 80% identity with those sequences

illustrated in the figures or fragments thereof. That is, 80% of the residues are the same. In a further embodiment, polypeptides will have greater than 80% identity. In a further embodiment, polypeptides will have greater than 85% identity. In 5 a further embodiment, polypeptides will have greater than 90% identity. In a further embodiment, polypeptides will have greater than 95% identity. In a further embodiment, polypeptides will have greater than 99% identity. In a further embodiment, analogs of polypeptides of the invention will have 10 fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10.

These substitutions are those having a minimal influence on the secondary structure and hydrophobic nature of the polypeptide. 15 Preferred substitutions are those known in the art as conserved, i.e. the substituted residues share physical or chemical properties such as hydrophobicity, size, charge or functional groups. These include substitutions such as those described by Dayhoff, M. in *Atlas of Protein Sequence and Structure* 5, 1978 20 and by Argos, P. in *EMBO J.* 8, 779-785, 1989. For example, amino acids, either natural or unnatural, belonging to one of the following groups represent conservative changes:
ala, pro, gly, gln, asn, ser, thr, val;
cys, ser, tyr, thr;
25 val, ile, leu, met, ala, phe;
lys, arg, orn, his;
and phe, tyr, trp, his.

The preferred substitutions also include substitutions of D-enantiomers for the corresponding L-amino acids.

30

In an alternative approach, the analogs could be fusion polypeptides, incorporating moieties which render purification easier, for example by effectively tagging the desired polypeptide. It may be necessary to remove the "tag" or it may 35 be the case that the fusion polypeptide itself retains sufficient antigenicity to be useful.

The percentage of homology is defined as the sum of the percentage of identity plus the percentage of similarity or conservation of amino acid type.

5 In one embodiment, analogs of polypeptides of the invention will have about 70% identity with those sequences illustrated in the figures or fragments thereof. That is, 70% of the residues are the same. In a further embodiment, polypeptides will have greater than 80% identity. In a further embodiment, polypeptides 10 will have greater than 85% identity. In a further embodiment, polypeptides will have greater than 90% identity. In a further embodiment, polypeptides will have greater than 95% identity. In a further embodiment, polypeptides will have greater than 99% identity. In a further embodiment, analogs of polypeptides of 15 the invention will have fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10.

In one embodiment, analogs of polypeptides of the invention will 20 have about 70% homology with those sequences illustrated in the figures or fragments thereof. In a further embodiment, polypeptides will have greater than 80% homology. In a further embodiment, polypeptides will have greater than 85% homology. In a further embodiment, polypeptides will have greater than 90% 25 homology. In a further embodiment, polypeptides will have greater than 95% homology. In a further embodiment, polypeptides will have greater than 99% homology. In a further embodiment, analogs of polypeptides of the invention will have fewer than about 20 amino acid residue substitutions, 30 modifications or deletions and more preferably less than 10.

One can use a program such as the CLUSTAL program to compare amino acid sequences. This program compares amino acid sequences and finds the optimal alignment by inserting spaces in 35 either sequence as appropriate. It is possible to calculate amino acid identity or homology for an optimal alignment. A program like BLASTx will align the longest stretch of similar sequences and assign a value to the fit. It is thus possible to obtain a comparison where several regions of similarity are

found, each having a different score. Both types of identity analysis are contemplated in the present invention.

In an alternative approach, the analogs or derivatives could be 5 fusion polypeptides, incorporating moieties which render purification easier, for example by effectively tagging the desired protein or polypeptide, it may be necessary to remove the "tag" or it may be the case that the fusion polypeptide itself retains sufficient antigenicity to be useful.

10

It is well known that it is possible to screen an antigenic polypeptide to identify epitopic regions, i.e. those regions which are responsible for the polypeptide's antigenicity or immunogenicity. Methods for carrying out such screening are 15 well known in the art. Thus, the fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties.

20 Thus, for fragments according to the present invention the degree of identity is perhaps irrelevant, since they may be 100% identical to a particular part of a polypeptide, analog as described herein.

25 Thus, what is important for analogs, derivatives and fragments is that they possess at least a degree of the antigenicity/immunogenicity of the protein or polypeptide from which they are derived.

30 Also included are polypeptides which have fused thereto other compounds which alter the polypeptides biological or pharmacological properties i.e. polyethylene glycol (PEG) to increase half-life; leader or secretory amino acid sequences for ease of purification; prepro- and pro- sequences; and 35 (poly)saccharides.

Furthermore, in those situations where amino acid regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the different epitopes of the different Moraxella strains.

5

Moreover, the polypeptides of the present invention can be modified by terminal -NH₂ acylation (eg. by acetylation, or thioglycolic acid amidation, terminal carboxy amidation, e.g. with ammonia or methylamine) to provide stability, increased 10 hydrophobicity for linking or binding to a support or other molecule.

Also contemplated are hetero and homo polypeptide multimers of the polypeptide fragments and analogues. These polymeric forms 15 include, for example, one or more polypeptides that have been cross-linked with cross-linkers such as avidin/biotin, gluteraldehyde or dimethylsuperimide. Such polymeric forms also include polypeptides containing two or more tandem or inverted contiguous sequences, produced from multicistronic 20 mRNAs generated by recombinant DNA technology.

In a further embodiment, the present invention also relates to chimeric polypeptides which comprise one or more polypeptides or fragments or analogs thereof as defined in the figures of the 25 present application.

In a further embodiment, the present invention also relates to chimeric polypeptides comprising two or more polypeptides having a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs 30 thereof; provided that the polypeptides are linked as to form a chimeric polypeptide.

In a further embodiment, the present invention also relates to chimeric polypeptides comprising two or more polypeptides 35 comprising a sequence chosen from SEQ ID NO: 2 or 4 provided that the polypeptides are linked as to form a chimeric polypeptide.

Preferably, a fragment, analog or derivative of a polypeptide of

the invention will comprise at least one antigenic region i.e. at least one epitope.

In order to achieve the formation of antigenic polymers (i.e. 5 synthetic multimers), polypeptides may be utilized having bishaloacetyl groups, nitroarylhalides, or the like, where the reagents being specific for thio groups. Therefore, the link between two mercapto groups of the different polypeptides may be a single bond or may be composed of a linking group of at least 10 two, typically at least four, and not more than 16, but usually not more than about 14 carbon atoms.

In a particular embodiment, polypeptide fragments and analogs of the invention do not contain a methionine (Met) starting 15 residue. Preferably, polypeptides will not incorporate a leader or secretory sequence (signal sequence). The signal portion of a polypeptide of the invention may be determined according to established molecular biological techniques. In general, the polypeptide of interest may be isolated from a Moraxella culture 20 and subsequently sequenced to determine the initial residue of the mature protein and therefore the sequence of the mature polypeptide.

It is understood that polypeptides can be produced and/or used 25 without their start codon (methionine or valine) and/or without their leader peptide to favor production and purification of recombinant polypeptides. It is known that cloning genes without sequences encoding leader peptides will restrict the polypeptides to the cytoplasm of *E. coli* and will facilitate 30 their recovery (Glick, B.R. and Pasternak, J.J. (1998) Manipulation of gene expression in prokaryotes. In "Molecular biotechnology: Principles and applications of recombinant DNA", 2nd edition, ASM Press, Washington DC, p.109-143).

35 According to another aspect of the invention, there are also provided (i) a composition of matter containing a polypeptide of the invention, together with a carrier, diluent or adjuvant; (ii) a pharmaceutical composition comprising a polypeptide of the invention and a carrier, diluent or adjuvant; (iii) a

vaccine comprising a polypeptide of the invention and a carrier, diluent or adjuvant; (iv) a method for inducing an immune response against Moraxella, in a host, by administering to the host, an immunogenically effective amount of a polypeptide of the invention to elicit an immune response, e.g., a protective immune response to Moraxella; and particularly, (v) a method for preventing and/or treating a Moraxella infection, by administering a prophylactic or therapeutic amount of a polypeptide of the invention to a host in need.

10

According to another aspect of the invention, there are also provided (i) a composition of matter containing a polynucleotide of the invention, together with a carrier, diluent or adjuvant; (ii) a pharmaceutical composition comprising a polynucleotide of the invention and a carrier, diluent or adjuvant; (iii) a method for inducing an immune response against Moraxella, in a host, by administering to the host, an immunogenically effective amount of a polynucleotide of the invention to elicit an immune response, e.g., a protective immune response to Moraxella; and particularly, (iv) a method for preventing and/or treating a Moraxella infection, by administering a prophylactic or therapeutic amount of a polynucleotide of the invention to a host in need.

25 Before immunization, the polypeptides of the invention can also be coupled or conjugated to carrier proteins such as tetanus toxin, diphtheria toxin, hepatitis B virus surface antigen, poliomyelitis virus VP1 antigen or any other viral or bacterial toxin or antigen or any suitable proteins to stimulate the 30 development of a stronger immune response. This coupling or conjugation can be done chemically or genetically. A more detailed description of peptide-carrier conjugation is available in Van Regenmortel, M.H.V., Briand J.P., Muller S., Plaué S., «Synthetic Polypeptides as antigens» in Laboratory Techniques in 35 Biochemistry and Molecular Biology, Vol.19 (ed.) Burdou, R.H. & Van Knippenberg P.H. (1988), Elsevier New York.

According to another aspect, there are provided pharmaceutical compositions comprising one or more Moraxella polypeptides of

the invention in a mixture with a pharmaceutically acceptable adjuvant. Suitable adjuvants include (1) oil-in-water emulsion formulations such as MF59™, SAF™, Ribi™ ; (2) Freund's complete or incomplete adjuvant; (3) salts i.e. $AlK(SO_4)_2$, $AlNa(SO_4)_2$, $AlNH_4(SO_4)_2$, $Al(OH)_3$, $AlPO_4$, silica, kaolin; (4) saponin derivatives such as Stimulon™ or particles generated therefrom such as ISCOMs (immunostimulating complexes); (5) cytokines such as interleukins, interferons, macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF) ; (6) other substances such as carbon polynucleotides i.e. poly IC and poly AU, detoxified cholera toxin (CTB) and E.coli heat labile toxin for induction of mucosal immunity. A more detailed description of adjuvant is available in a review by M.Z.I Khan et al. in Pharmaceutical Research, vol. 11, No. 1 (1994) pp2-11, and also in another review by Gupta et al., in Vaccine, Vol. 13, No. 14, pp1263-1276 (1995) and in WO 99/24578. Preferred adjuvants include QuilA™, QS21™, Alhydrogel™ and Adjuphos™.

Pharmaceutical compositions of the invention may be administered 20 parenterally by injection, rapid infusion, nasopharyngeal absorption, dermoabsorption, or buccal or oral.

Pharmaceutical compositions of the invention are used for the prophylaxis of moraxella infection and/or diseases and symptoms 25 mediated by moraxella infection as described in Manual of Clinical Microbiology, P.R. Murray (Ed, in chief), E.J. Baron, M.A. Pfaffer, F.C. Tenover and R.H. Yolken. ASM Press, Washington, D.C. seventh edition, 1999, 1773p. In one embodiment, pharmaceutical compositions of the present invention 30 are used for the treatment or prophylaxis of otitis media, sinusitis, persistent cough, acute laryngitis, suppurative keratitis, conjunctivitis neonatorum. In one embodiment, vaccine compositions of the invention are used for the treatment or prophylaxis of moraxella infection and/or diseases and 35 symptoms mediated by moraxella infection. In a further embodiment, the moraxella infection is Moraxella Catarrhalis.

In a particular embodiment, pharmaceutical compositions are administered to those hosts at risk of moraxella infection such 40 as neonates, infants, children, elderly and immunocompromised

hosts.

As used in the present application, the term "host" includes mammals. In a further embodiment, the mammal is human. In a further embodiment, the human is a neonate, infant or child. In a further embodiment, the human is an adult.

In a particular embodiment, pharmaceutical compositions are administered to those hosts at risk of moraxella infection such as neonates, infants, children, elderly and immunocompromised hosts.

Pharmaceutical compositions are preferably in unit dosage form of about 0.001 to 100 µg/kg (antigen/body weight) and more preferably 0.01 to 10 µg/kg and most preferably 0.1 to 1 µg/kg 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.

Pharmaceutical compositions are preferably in unit dosage form of about 0.1 µg to 10 mg and more preferably 1µg to 1 mg and most preferably 10 to 100 µg 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.

According to another aspect, there are provided polynucleotides encoding polypeptides characterized by the amino acid sequence comprising SEQ ID NO: 2, 4 or fragments or analogs thereof.

In one embodiment, polynucleotides are those illustrated in SEQ ID No: 1, 3 which may include the open reading frames (ORF), encoding the polypeptides of the invention.

It will be appreciated that the polynucleotide sequences illustrated in the figures may be altered with degenerate codons yet still encode the polypeptides of the invention. Accordingly the present invention further provides polynucleotides which hybridize to the polynucleotide sequences herein above described (or the complement sequences thereof) having 70% identity between sequences. In one embodiment, at least 80% identity between sequences. In one embodiment, at least 85% identity

between sequences. In one embodiment, at least 90% identity between sequences. In a further embodiment, polynucleotides are hybridizable under stringent conditions i.e. having at least 95% identity. In a further embodiment, more than 97% identity.

5

Suitable stringent conditions for hybridization can be readily determined by one of skilled in the art (see for example Sambrook et al., (1989) Molecular cloning : A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology, (1999) Edited by Ausubel F.M. et al., John Wiley & Sons, Inc., N.Y.).

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to 15 either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises SEQ ID NO: 2, 4 or fragments 20 or analogs thereof.

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

25 (a) a DNA sequence encoding a polypeptide or
(b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises SEQ ID NO: 2 or 4.

30 In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a 35 polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising SEQ ID NO: 2, 4 or fragments or analogs thereof.

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

5 (a) a DNA sequence encoding a polypeptide or
(b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising SEQ ID NO: 2 or 4.

In a further embodiment, polynucleotides are those illustrated 10 in SEQ ID NO: 1, 3 or fragments or analogs thereof encoding polypeptides of the invention.

In a further embodiment, polynucleotides are those illustrated in SEQ ID NO: 1, 3 encoding polypeptides of the invention.

15

As will be readily appreciated by one skilled in the art, polynucleotides include both DNA and RNA.

The present invention also includes polynucleotides 20 complementary to the polynucleotides described in the present application.

In a further aspect, polynucleotides encoding polypeptides of the invention, or fragments, analogs or derivatives thereof, may 25 be used in a DNA immunization method. That is, they can be incorporated into a vector which is replicable and expressible upon injection thereby producing the antigenic polypeptide in vivo. For example polynucleotides may be incorporated into a plasmid vector under the control of the CMV promoter which is 30 functional in eukaryotic cells. Preferably the vector is injected intramuscularly.

According to another aspect, there is provided a process for producing polypeptides of the invention by recombinant 35 techniques by expressing a polynucleotide encoding said polypeptide in a host cell and recovering the expressed polypeptide product. Alternatively, the polypeptides can be produced according to established synthetic chemical techniques i.e. solution phase or solid phase synthesis of oligopeptides

which are ligated to produce the full polypeptide (block ligation).

General methods for obtention and evaluation of polynucleotides and polypeptides are described in the following references: 5 Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y., 1989; Current Protocols in Molecular Biology, Edited by Ausubel F.M. et al., John Wiley and Sons, Inc. New York; PCR Cloning Protocols, from Molecular Cloning to 10 Genetic Engineering, Edited by White B.A., Humana Press, Totowa, New Jersey, 1997, 490 pages; Protein Purification, Principles and Practices, Scopes R.K., Springer-Verlag, New York, 3rd Edition, 1993, 380 pages; Current Protocols in Immunology, Edited by Coligan J.E. et al., John Wiley & Sons Inc., New York.

15

The present invention provides a process for producing a polypeptide comprising culturing a host cell of the invention under conditions suitable for expression of said polypeptide.

20 For recombinant production, host cells are transfected with vectors which encode the polypeptides of the invention, and then cultured in a nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes. Suitable vectors are those that are viable and replicable 25 in the chosen host and include chromosomal, non-chromosomal and synthetic DNA sequences e.g. bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA. The polypeptide sequence may be incorporated in the vector at the appropriate site using 30 restriction enzymes such that it is operably linked to an expression control region comprising a promoter, ribosome binding site (consensus region or Shine-Dalgarno sequence), and optionally an operator (control element). One can select individual components of the expression control region that are 35 appropriate for a given host and vector according to established molecular biology principles (Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y., 1989; Current Protocols in Molecular Biology, Edited by Ausubel F.M. et al., John Wiley and Sons, Inc. New York). Suitable promoters 40 include but are not limited to LTR or SV40 promoter, E.coli lac,

tac or trp promoters and the phage lambda P_L promoter. Vectors will preferably incorporate an origin of replication as well as selection markers i.e. ampicillin resistance gene. Suitable bacterial vectors include pET, pQE70, pQE60, pQE-9, pD10 5 phagescript, pSiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 and eukaryotic vectors pBlueBacIII, pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG and pSVL. Host cells may be bacterial i.e. E.coli, Bacillus subtilis, Streptomyces; fungal i.e. 10 Aspergillus niger, Aspergillus nidulans; yeast i.e. Saccharomyces or eukaryotic i.e. CHO, COS.

Upon expression of the polypeptide in culture, cells are typically harvested by centrifugation then disrupted by physical 15 or chemical means (if the expressed polypeptide is not secreted into the media) and the resulting crude extract retained to isolate the polypeptide of interest. Purification of the polypeptide from culture media or lysate may be achieved by established techniques depending on the properties of the 20 polypeptide i.e. using ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography. Final purification may be achieved using 25 HPLC.

The polypeptides may be expressed with or without a leader or secretion sequence. In the former case the leader may be removed using post-translational processing (see US 4,431,739; 30 US 4,425,437; and US 4,338,397) or be chemically removed subsequent to purifying the expressed polypeptide.

According to a further aspect, the Moraxella polypeptides of the invention may be used in a diagnostic test for Moraxella 35 infection, in particular Moraxella infection. Several diagnostic methods are possible, for example detecting Moraxella organism in a biological sample, the following procedure may be followed:

- a) obtaining a biological sample from a host;

- b) incubating an antibody or fragment thereof reactive with a polypeptide of the invention with the biological sample to form a mixture; and
- c) detecting specifically bound antibody or bound fragment in 5 the mixture which indicates the presence of Moraxella.

Alternatively, a method for the detection of antibody specific to a Moraxella antigen in a biological sample containing or suspected of containing said antibody may be performed as 10 follows:

- a) obtaining a biological sample from a host;
- b) incubating one or more polypeptides of the invention or fragments thereof with the biological sample to form a mixture; and
- 15 c) detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to Moraxella.

One of skill in the art will recognize that this diagnostic test 20 may take several forms, including an immunological test such as an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay or a latex agglutination assay, essentially to determine whether antibodies specific for the protein are present in an organism.

25 The DNA sequences encoding polypeptides of the invention may also be used to design DNA probes for use in detecting the presence of Moraxella in a biological sample suspected of containing such bacteria. The detection method of this invention comprises:

- 30 a) obtaining the biological sample from a host;
- b) incubating one or more DNA probes having a DNA sequence encoding a polypeptide of the invention or fragments thereof with the biological sample to form a mixture; and
- 35 c) detecting specifically bound DNA probe in the mixture which indicates the presence of Moraxella bacteria.

The DNA probes of this invention may also be used for detecting 40 circulating Moraxella i.e. Moraxella nucleic acids in a sample, for example using a polymerase chain reaction, as a method of

diagnosing Moraxella infections. The probe may be synthesized using conventional techniques and may be immobilized on a solid phase, or may be labelled with a detectable label. A preferred DNA probe for this application is an oligomer having a sequence 5 complementary to at least about 6 contiguous nucleotides of the Moraxella polypeptides of the invention.

Another diagnostic method for the detection of Moraxella in a host comprises:

- 10 a) labelling an antibody reactive with a polypeptide of the invention or fragment thereof with a detectable label;
- b) administering the labelled antibody or labelled fragment to the host; and
- 15 c) detecting specifically bound labelled antibody or labelled fragment in the host which indicates the presence of Moraxella.

A further aspect of the invention is the use of the Moraxella 20 polypeptides of the invention as immunogens for the production of specific antibodies for the diagnosis and in particular the treatment of Moraxella infection. Suitable antibodies may be determined using appropriate screening methods, for example by measuring the ability of a particular antibody to passively 25 protect against Moraxella infection in a test model. One example of an animal model is the mouse model described in the examples herein. The antibody may be a whole antibody or an antigen-binding fragment thereof and may belong to any immunoglobulin class. The antibody or fragment may be of animal 30 origin, specifically of mammalian origin and more specifically of murine, rat or human origin. It may be a natural antibody or a fragment thereof, or if desired, a recombinant antibody or antibody fragment. The term recombinant antibody or antibody 35 fragment means antibody or antibody fragment which was produced using molecular biology techniques. The antibody or antibody fragments may be polyclonal, or preferably monoclonal. It may be specific for a number of epitopes associated with the Moraxella polypeptides but is preferably specific for one.

According to one aspect, the present invention provides the use of an antibody for treatment and/or prophylaxis of Moraxella infections.

5 A further aspect of the invention is the use of the antibodies directed to the polypeptides of the invention for passive immunization. One could use the antibodies described in the present application.

10 A further aspect of the invention is a method for immunization, whereby an antibody raised by a polypeptide of the invention is administered to a host in an amount sufficient to provide a passive immunization.

15 In a further embodiment, the invention provides the use of a pharmaceutical composition of the invention in the manufacture of a medicament for the prophylactic or therapeutic treatment of Moraxella infection.

20 In a further embodiment, the invention provides a kit comprising a polypeptide of the invention for detection or diagnosis of Moraxella infection.

Unless otherwise defined, all technical and scientific terms 25 used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, 30 including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

35 EXAMPLE 1

This example illustrates the cloning and molecular characteristics of BVH-MC6 gene and corresponding polypeptide.

The coding region of M. catarrhalis BVH-MC6 (SEQ ID NO: 1) gene was amplified by PCR (DNA Thermal Cycler GeneAmp PCR system 2400 Perkin Elmer, San Jose, CA) from genomic DNA of M. catarrhalis strain ETSU C-2 using the following oligos that contained base 5 extensions for the addition of restriction sites *Nde*I (CATATG) and *Xho*I (CTCGAG): DMAR598 (5'-TAAGGATACATATGACGGCCCATAAAGATCG-3'); DMAR599 (5'-TATGCTCGAGGTATACTTGACTGGCTTATCATGTG-3'). PCR products were purified from agarose gel using a QIAquick gel extraction kit from QIAGen following the manufacturer's 10 instructions (Chatsworth, CA), and digested with *Nde*I and *Xho*I (Amersham Pharmacia Biotech, Inc, Baie d'Urfé, Canada). The pET21b(+) vector (Novagen, Madison, WI) was digested with *Nde*I and *Xho*I and purified from agarose gel using a QIAquick gel extraction kit from QIAGen (Chatsworth, CA). The *Nde*I-*Xho*I PCR 15 products were ligated to the *Nde*I-*Xho*I pET21b(+) expression vector. The ligated products were transformed into E. coli strain DH5 α [φ80dlacZΔM15 Δ(*lacZYA-argF*)U169 *endA1* *recA1* *hsdR*17(*r_k-m_k*+) *deoR* *thi-1* *supE44* λ -*gyrA96* *relA1*] (Gibco BRL, Gaithersburg, MD) according to the method of Simanis (Hanahan, 20 D. DNA Cloning, 1985, D.M. Glover (ed), pp. 109-135). Recombinant pET21b(+) plasmid (rpET21b(+)) containing BVH-MC6 gene was purified using a QIAGen kit (Chatsworth, CA) and DNA insert was sequenced (Taq Dye Deoxy Terminator Cycle Sequencing kit, ABI, Foster City, CA).

25

Table 1. Oligonucleotide primers used for PCR amplification of *M. catarrhalis* genes.

Genes	Primers I.D.	Restriction site	Vector	Sequence
BVH-MC6	DMAR598	<i>Nde</i> I	pET21b (+)	5'- TAAGGATACATATGACGGC CCATAAAGATCG -3' (SEQ ID NO:5)
BVH-MC6	DMAR599	<i>Xho</i> I	pET21b (+)	5'- TATGCTCGAGGTATACTTT GACTGGCTTATCATGTG - 3' (SEQ ID NO:6)
BVH-MC6	RIOS136	<i>Bam</i> HI	pCMV-GH	5'- GAGTGC GGATCCTGATGAC CGCCCAAAT-3' (SEQ ID NO:7)
BVH-MC6	RIOS137	<i>Hind</i> III	pCMV-GH	5'- TGTATTAAGCTTTAGTAT ACTTGACTGGCTTATC- 3' (SEQ ID NO:8)
BVH-MC7	DMAR594	<i>Nde</i> I	pET21b (+)	5'- CGGATATTCAATATGTATCA GCGCTTTATCAATAC- 3' (SEQ ID NO:9)
BVH-MC7	DMAR691	<i>Xho</i> I	pET21b (+)	5'- ATAGATCTCGAGAAATTGC CAAACAGTCACA-3' (SEQ ID NO:10)
BVH-MC7	RIOS134	<i>Bgl</i> II	pCMV-GH	5'- ACTATGAGATCTGGGCAC CAAAGCCATCAAGC- 3' (SEQ ID NO:11)
BVH-MC7	RIOS135	<i>Sal</i> I	pCMV-GH	5'- GATTATGTCGACTTAAAAT TGCCAAACAGTCACAAC- 3' (SEQ ID NO:12)

It was determined that the open reading frame (ORF) which codes for BVH-MC6 polypeptide contains 1005-bp and encodes a 334 amino acid residues polypeptide with a predicted pi of 5.46 and a predicted molecular mass of 36662.14 Da. Analysis of the predicted amino acid residues sequence (SEQ ID NO :2) using the Spscan sofware (Wisconsin Sequence Analysis Package; Genetics Computer Group) suggested the existence of a 39 amino acid residues signal peptide (MTAHKDRSTNL SKICLKHCFFTSSLIATLAMGLAMSACS),

which ends with a cleavage site located between a serine and an aspartic acid residues.

To confirm the presence by PCR amplification of BVH-MC6 (SEQ ID NO:1) gene, the following 4 distinct M. catarrhalis strains were used: M. catarrhalis ETSU C-2, ETSU T-25, and ETSU 658 clinical isolates were provided by the East Tennessee State University; M. catarrhalis strain M-12 was provided by the Centre de Recherche en Infectiologie du Centre Hospitalier de l'Université Laval. The E. coli XL1-Blue MRF' was used in these experiments as negative control. BVH-MC6 (SEQ ID NO :1) gene was amplified by PCR (DNA Thermal Cycler GeneAmp PCR system 2400 Perkin Elmer, San Jose, CA) from genomic DNA from the 4 M. catarrhalis strains, and the control E. coli strain using the oligonucleotides primers DMAR598 and DMAR599 (Table 1). PCR was performed with 35 cycles of 30 sec at 94°C, 30 sec at 50°C and 1 min at 72°C and a final elongation period of 10 min at 72°C. The PCR products were size fractionated in 1% agarose gels and were visualized by ethidium bromide staining. The results of these PCR amplifications are presented in Table 2. The analysis of the amplification products revealed that BVH-MC6 (SEQ ID NO :1) gene was present in the genome of all of the 4 M. catarrhalis strains tested. No such product was detected when the control E. coli DNA was submitted to identical PCR amplifications with these 25 oligonucleotide primers.

Table 2. Identification of M. catarrhalis genes by PCR amplification.

Strain Identification	Identification by PCR amplification of	
	BVH-MC6	BVH-MC7
ETSU C-2	+	+
ETSU 658	+	+
ETSU T-25	+	+
M-12	+	+
<u>E. coli</u>	-	-

EXAMPLE 2

This example illustrates the cloning and molecular characteristics of BVH-MC7 gene and corresponding polypeptide.

5 The coding region of M. catarrhalis BVH-MC7 (SEQ ID NO: 3) gene was amplified by PCR (DNA Thermal Cycler GeneAmp PCR system 2400 Perkin Elmer, San Jose, CA) from genomic DNA of M. catarrhalis strain ETSU C-2 using the following oligos that contained base extensions for the addition of restriction sites *Nde*I (CATATG)

10 and *Xho*I (CTCGAG): DMAR594 and DMAR691, which are presented in Table 1. The methods used for cloning BVH-MC7 into an expression vector and sequencing are similar to the methods described in Example 1.

15 It was determined that the open reading frame (ORF) which codes for BVH-MC7 contains 1179-bp and encodes a 392 amino acid residues polypeptide with a predicted pI of 8.65 and a predicted molecular mass of 41456.50 Da. Analysis of the predicted amino acid residues sequence (SEQ ID NO :4) using the Spscan software 20 (Wisconsin Sequence Analysis Package; Genetics Computer Group) suggested the existence of a 21 amino acid residues signal peptide (MYQRFINTALVAALAVTMAGC), which ends with a cleavage site located between a cysteine and a glycine residues.

25 The BVH-MC7 gene was shown to be present after PCR amplification using the oligonucleotide primers DMAR594 and DMAR691 in the 4 M. catarrhalis strains tested (Table 2). The methods used for PCR amplification of the BVH-MC7 gene were similar to the methods presented in Example 1. No such product was detected 30 when the control E. coli DNA was submitted to identical PCR amplification with these oligonucleotide primers.

EXAMPLE 3

35 This example illustrates the cloning of M. catarrhalis genes in CMV plasmid pCMV-GH.

The DNA coding regions of a M. catarrhalis polypeptides were inserted in phase downstream of a human growth hormone (hGH) 40 gene which was under the transcriptional control of the

cytomegalovirus (CMV) promotor in the plasmid vector pCMV-GH (Tang et al., *Nature*, 1992, 356 :152). The CMV promotor is non-functional plasmid in *E. coli* cells but active upon administration of the plasmid in eukaryotic cells. The vector 5 also incorporated the ampicillin resistance gene.

The coding regions of BVH-MC6 (SEQ ID NO: 1) and BVH-MC7 (SEQ ID NO: 3) genes without their leader peptide regions were amplified by PCR (DNA Thermal Cycler GeneAmp PCR system 2400 Perkin Elmer, 10 San Jose, CA) from genomic DNA of M. catarrhalis strain ETSU C-2 using oligonucleotide primers that contained base extensions for the addition of restriction sites *Bam*HI (GGATCC), *Bgl*II (AGATCT), *Sal*I (GTGAC), or *Hind*III (AAGCTT) which are described in Table 1. The PCR products were purified from agarose gel 15 using a QIAquick gel extraction kit from QIAgen (Chatsworth, CA), digested with restriction enzymes (Amersham Pharmacia Biotech, Inc, Baie d'Urfe, Canada). The pCMV-GH vector (Laboratory of Dr. Stephen A. Johnston, Department of Biochemistry, The University of Texas, Dallas, Texas) was 20 digested with *Bam*HI, *Bgl*II, *Sal*I, or *Hind*III and purified from agarose gel using the QIAquick gel extraction kit from QIAgen (Chatsworth, CA). The digested DNA fragments were ligated to the digested pCMV-GH vector to create the hGH-BVH-MC6 and hGH-BVH-MC7 fusion polypeptides under the control of the CMV 25 promoter. The ligated products were transformed into E. coli strain DH5 α [φ80dlacZΔM15 Δ(*lacZYA-argF*)U169 *endA1* *recA1* *hsdR17*(r_k-m_k+) *deoR* *thi-1* *supE44* λ^r*gyrA96* *relA1*] (Gibco BRL, Gaithersburg, MD) according to the method of Simanis (Hanahan, D. DNA Cloning, 1985, D.M. Glover (ed), pp. 109-135). The 30 recombinant pCMV plasmids were purified using a QIAgen kit (Chatsworth, CA) and the nucleotide sequences of the DNA inserts were verified by DNA sequencing.

35 EXAMPLE 4

This example illustrates the use of DNA to elicit an immune response to M. catarrhalis polypeptide antigens.

A group of 8 female BALB/c mice (Charles River, St-Constant, 40 Québec, Canada) were immunized by intramuscular injection of 100

μl three times at two- or three-week intervals with 50 μg of recombinant pCMV-GH encoding BVH-MC6 (SEQ ID NO: 1) and BVH-MC7 (SEQ ID NO: 3) genes in presence of 50 μg of granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing 5 plasmid pCMV-GH-GM-CSF (Laboratory of Dr. Stephen A. Johnston, Department of Biochemistry, The University of Texas, Dallas, Texas). As control, a group of mice were injected with 50 μg of pCMV-GH in presence of 50 μg of pCMV-GH-GM-CSF. Blood samples were collected from the orbital sinus prior to each immunization 10 and seven days following the third injection and serum antibody responses were determined by ELISA using the corresponding His-Tag labeled M. catarrhalis recombinant polypeptides as coating antigen. The production and purification of these His-tagged labeled M. catarrhalis recombinant polypeptides are presented in 15 Example 5.

EXAMPLE 5

This example illustrates the production and purification of M. catarrhalis recombinant polypeptides.

The recombinant pET21b(+) plasmid with BVH-MC6 (SEQ ID NO: 1) and BVH-MC7 (SEQ ID NO: 3) genes were used to transform by 25 electroporation (Gene Pulser II apparatus, BIO-RAD Labs, Mississauga, Canada) E. coli strain AD494 (DE3) [Δ ara-leu7697 Δ lacX74 Δ phoA Pvu II $phoR$ Δ malF3 F' [lac^+ ($lacI^q$) pro] trx B::Kan (DE3)] (Novagen, Madison, WI). In this strain of E. coli, the T7 promotor controlling expression of the recombinant polypeptide is specifically recognized by the T7 RNA polymerase 30 (present on the λ DE3 prophage) whose gene is under the control of the lac promotor which is inducible by isopropyl- β -d-thiogalactopyranoside (IPTG). The transformant AD494(DE3)/rpET21b(+) was grown at 37°C with agitation at 250 rpm in LB broth (peptone 10g/L, yeast extract 5g/L, NaCl 10g/L) containing 35 100 μg of carbenicillin (Sigma-Aldrich Canada Ltd., Oakville, Canada) per ml until the A_{600} reached a value of 0.5. In order to induce the production of His-tagged M. catarrhalis recombinant polypeptides, the cells were incubated for 3 additional hours in the presence of IPTG at a final concentration of 1 mM. Induced

cells from a 500 ml culture were pelleted by centrifugation and frozen at -70°C.

The purification of the recombinant polypeptides from the 5 soluble cytoplasmic fraction of IPTG-induced AD494(DE3)/rpET21b(+) was done by affinity chromatography based on the properties of the His•Tag sequence (6 consecutive histidine residues) to bind to divalent cations (Ni²⁺) immobilized on the His•Bind metal chelation resin. Briefly, the 10 pelleted cells obtained from a 500 mL culture induced with IPTG was resuspended in lysis buffer (20 mM Tris, 500 mM NaCl, 10 mM imidazole, pH 7.9) containing 1mM PMSF, sonicated and centrifuged at 12,000 X g for 20 min to remove debris. The supernatant was deposited on a Ni-NTA agarose column (Qiagen, 15 Mississauga, Ontario, Canada). The His-tagged labeled M. catarrhalis recombinant polypeptides were eluted with 250 mM imidazole-500mM NaCl-20 mM Tris pH 7.9. The removal of the salt and imidazole from the sample was done by dialysis against PBS at 4°C. The quantities of recombinant polypeptides obtained from 20 the soluble fraction of E. coli were estimated by MicroBCA (Pierce, Rockford, Illinois).

EXAMPLE 6

25 This example illustrates the reactivity of the His-tagged M. catarrhalis recombinant polypeptides with antibodies present in human palatine tonsils and sera collected from mice after immunization with M. catarrhalis antigenic preparations.

30 As shown in Table 3, BVH-MC6 His-tagged recombinant polypeptide was recognized in immunoblots by the antibodies present in the human palatine tonsils. It indicates that humans, which are normally in contact with M. catarrhalis do develop antibodies that are specific to this polypeptide. These particular human 35 antibodies might be implicated in the protection against M. catarrhalis infection. In addition, immunoblots also revealed that sera collected from mice immunized with M. catarrhalis antigenic preparation enriched membrane proteins which induced significant lung clearance in a mouse model also developed

antibodies that recognized BVH-MC7 His-tagged recombinant polypeptides. These results indicate that this protein was present in M. catarrhalis antigenic preparation that protected mice against infection and that it induced antibodies that reacted with the corresponding BVH-MC7 His-tagged recombinant polypeptide.

Table 3. Reactivity in immunoblots of antibodies present in human palatine tonsils and sera collected from mice after immunization with M. catarrhalis antigenic preparations with M. catarrhalis His-tagged fusion recombinant polypeptides.

Purified recombinant polypeptide I.D. ¹	Apparent molecular weight (kDa) ²	Reactivity in immunoblots with	
		Human palatine tonsils ³	Mouse sera ⁴
BVH-MC6	38	+	-
BVH-MC7	42	-	+

¹His-tagged recombinant polypeptides produced and purified as described in Example 5 were used to perform the immunoblots.

²Molecular weight of the His-tagged recombinant polypeptide was estimated after SDS-PAGE.

³Extracts from human palatine tonsils were not diluted in order to perform the immunoblots.

⁴Mouse sera collected after immunization with M. catarrhalis antigenic preparations enriched membrane polypeptides were pooled and diluted 1/500 to perform the immunoblots. These mice were protected against M. catarrhalis challenge.

EXAMPLE 7

This example illustrates the accessibility to antibodies of the BVH-MC6 and BVH-MC7 polypeptides at the surface of M. catarrhalis strain.

Bacteria were grown in Brain Heart Infusion (BHI) broth containing 0.25% dextrose at 37°C in a 8% CO₂ atmosphere to give an OD_{490nm} of 0.650 (~10⁸ CFU/ml). Dilutions of anti-BVH-MC6 or anti-BVH-MC7 or control sera were then added and allowed to bind to the cells, which were incubated for 2 h at 4°C with rotation.

Samples were washed 4 times in blocking buffer [phosphate-buffered saline (PBS) containing 2% bovine serum albumin (BSA)], and then 1 ml of goat fluorescein (FITC)-conjugated anti-mouse IgG Fc (gamma) fragment specific diluted in blocking buffer was 5 added. After an additional incubation of 60 min at room temperature with rotation in the dark, samples were washed 4 times in blocking buffer and fixed with 0.25 % formaldehyde in PBS buffer for 18 h at 4°C. Cells were washed 2 times in PBS buffer and resuspended in 0.5 ml of PBS buffer. Cells were kept 10 in the dark at 4°C until analyzed by flow cytometry (Epics® XL; Beckman Coulter, Inc.). Flow cytometric analysis revealed that BVH-MC6- and BVH-MC7-specific antibodies efficiently recognized their corresponding surface exposed epitopes on the homologous (ETSU C-2) M. catarrhalis strain tested (Table 4). It was 15 determined that more than 60 % of the 10,000 Moraxella cells analyzed were labeled with the antibodies present in the BVH-MC6- and BVH-MC7-specific sera. In addition, antibodies present in the pool of BVH-MC6- and BVH-MC7-specific sera attached at the surface of ETSU 658 and M-12 strains of M. catarrhalis 20 (Table 4). It was also determined that more than 90% of the 10,000 cells of each of the two latter strains were labeled by the specific antibodies. These observations clearly demonstrate that the BVH-MC6 and BVH-MC7 polypeptides are accessible at the surface, where they can be easily recognized by antibodies. 25 Anti-M. catarrhalis antibodies were shown to play an important role in the protection against M. catarrhalis infection.

Table 4. Evaluation of the attachment of BVH-MC6- and BVH-MC7- 30 specific antibodies at the surface of intact cells of M. catarrhalis.

Serum Identification	Strains	Fluorescence Index ²	% of labeled cells ³
Pool of BVH-MC6- specific sera ¹	ETSU C-2	17.1	78.6
	ETSU 658	23.9	93.6
	M-12	28.8	95.3
	ETSU C-2	14.1	63.8

Pool of BVH-MC7-specific sera	ETSU 658	16.9	91.3
	M-12	20.6	93.0
Pool of negative control sera ⁴	ETSU C-2	1	1
	ETSU 658	1	1
	M-12	1	11.3
Positive control serum ⁵	ETSU C-2	35.3	91.9
	ETSU 658	23.4	96.0
	M-12	16.5	84.0

¹ The mice were injected subcutaneously three times at two-week intervals with 20 µg of purified recombinant polypeptides mixed with 10 µg of QuilA adjuvant (Cedarlane Laboratories, Hornby, Canada). The sera were diluted 1/50.

² The fluorescence index was calculated as the median fluorescence value obtained after labeling the cells with an immune serum divided by the fluorescence value obtained for a control mouse serum. A fluorescence value of 1 indicated that there was no binding of antibodies at the surface of intact 10 Moraxella cells.

³% of labeled cells out of the 10,000 cells analyzed.

⁴ Sera collected from unimmunized or sham-immunized mice were pooled, diluted 1/50, and used as negative controls for this assay.

¹⁵ ⁵Serum obtained from a mouse immunized with 20 µg of purified outer membrane polypeptides from M. catarrhalis strain ETSU-C2 was diluted 1/1000 and was used as a positive control for the assay.

20

EXAMPLE 8

This example illustrates the bactericidal activities of anti-BVH-MC6 mouse sera.

²⁵ Bacteria were plated on chocolate agar plate and incubated at 37°C in a 8% CO₂ atmosphere for 18 h. Bacterial cells were then resuspended in bacteriolysis buffer [10% Hanks' Balanced Salt Solution (HBSS) and 1% hydrolyzed casein, pH 7.3] to an OD_{490nm} of

0.25 and diluted to 8×10^4 CFU/ml. The bactericidal assay was performed by mixing 25 μ l of the bacterial suspension with 50 μ l of diluted heat-inactivated test serum and 15 μ l of HBSS and incubating for 15 min at 37°C, 8% CO₂ with agitation (200rpm).
 5 The rabbit complement-containing serum was then added to a final concentration of 10%, and the mixture was incubated for an additional 60 min at 37°C, 8% CO₂ with agitation (200rpm). At the end of the incubation period, the number of viable bacteria was determined by plating 10 μ l of the assay mixture on chocolate
 10 agar plate. The plates were incubated at 37°C in an 8% CO₂ atmosphere for 18-24 h. The control consisted of bacteria incubated with heat-inactivated sera collected from mice before immunization and rabbit complement. The M. catarrhalis strain ETSU 658 was used to evaluate the bactericidal activity of the
 15 sera. The % of lysis was determined by the following mathematical formula:

$$100 - \left[\frac{\text{CFU obtained when the bacteria were incubated with immune sera}}{\text{CFU obtained with pre-bleed sera}} \times 100 \right]$$

20

Bactericidal antibodies were found to be present in the sera collected from 7 mice immunized with the purified recombinant BVH-MC6 protein (Table 5). No bactericidal activity were recorded in the sera collected from control mice (data not
 25 shown).

Table 5. Evaluation of the bactericidal activity of anti-BVH-MC6 mouse sera.

Serum identification ¹	% of lysis
S1 ²	97.2
S2	9.7
S3	99.1
S4	98.8
S5	82.9
S6	94.6
S7	93.2
S8	70.9
Positive control serum ³	76.0

¹The mice S1 to S8 were injected subcutaneously five times at
 30 two-week intervals with 20 μ g of purified recombinant protein

mixed with 10 µg of QuilA adjuvant (Cedarlane Laboratories, Hornby, Canada).

²Each mouse serum collected from BVH-MC6 immunized mouse were diluted 1/50.

5 ³Serum obtained from a mouse immunized with 20 µg of purified outer membrane proteins was diluted 1/50 and was used as a positive control for the assay.

10 EXAMPLE 9

This example illustrates the protection of mice against M. catarrhalis infection induced by immunization.

Groups of 10 female BALB/c mice (Charles River) were immunized 15 subcutaneously three times at two-week intervals with 20 µg of affinity purified His-tagged M. catarrhalis recombinant polypeptides in presence of 10% of QuilA adjuvant (Cedarlane Laboratories Ltd, Hornby, Canada) or, as control, with QuilA adjuvant alone in PBS. Blood samples were collected from the 20 orbital sinus on day 0, 14, and 28 prior to each immunization and 14 days (day 42) following the third injection. One week later the mice were challenged intrapulmonary with approximately 1×10^6 CFU of the M. catarrhalis strain ETSU 658. Samples of the M. catarrhalis challenge inoculum were plated on chocolate agar 25 plates to determine the CFU and to verify the challenge dose. Mice were killed by an intraperitoneal injection of sodium pentobarbital (Euthanyl™) 5h after infection. The intact lungs were excised and homogenised in a tissue homogeniser. The lung homogenate were assessed for bacterial clearance by plating of 30 serial dilutions for CFU determination.

EXAMPLE 10

This example illustrates the protection of mice against M. catarrhalis infection induced by immunization with purified recombinant BVH-MC6.

Groups of 8 female BALB/c mice (Charles River) were immunized subcutaneously five times at two-week intervals with 20 µg of 40 affinity purified His-tagged M. catarrhalis recombinant BVH-MC6

polypeptide in presence of 10% of QuilA adjuvant (Cedarlane Laboratories Ltd, Hornby, Canada) or, as control, with QuilA adjuvant alone in PBS. Blood samples were collected from the orbital sinus on day 0, 14, 28, 42, and 56 prior to each 5 immunization and 14 days (day 70) following the fifth injection. One week later the mice were challenged intrapulmonary with approximately 9×10^5 CFU of the M. catarrhalis heterologous strain ETSU 658. Samples of the M. catarrhalis challenge inoculum were plated on chocolate agar plates to determine the CFU and to 10 verify the challenge dose. Mice were killed by an intraperitoneal injection of sodium pentobarbital (Euthanyl™) 5h after infection. The intact lungs were excised and homogenised in a tissue homogeniser. The lung homogenate were assessed for bacterial clearance by plating of serial dilutions for CFU 15 determination. As shown in Table 6, 60% fewer bacteria were recovered from the immunized mice than from the control group challenged in parallel. Thus, immunization with recombinant BVH-MC6 polypeptide promoted rapid clearance of a heterologous strain of M. catarrhalis from lungs of mice.

20

Table 6. Pulmonary clearance of Moraxella catarrhalis by mice immunized with purified recombinant BVH-MC6 polypeptide

Bacterial recovery from control group (CFU/ml of lung homogenate) ^a	Bacterial recovery from BVH-MC6 group (CFU/ml of lung homogenate) ^b	Bacterial clearance (%) ^c
$1.86 \times 10^5 \pm 1.01 \times 10^5$	$7.44 \times 10^4 \pm 2.17 \times 10^4$	60

^aMeans \pm standard deviations for seven mice.

^bMeans \pm standard deviations for eight mice.

25 ^cMice were challenged intrapulmonary with 9×10^5 CFU of bacteria, and viable bacteria were recovered from lung 5 h after challenge. The number is the percentage of bacteria cleared from immunized mice compared with that of the control.

What is claimed is:

1. An isolated polynucleotide comprising a polynucleotide chosen from:
 - (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4 or fragments or analogs thereof;
 - (b) a polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4 or fragments or analogs thereof;
 - (c) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4 or fragments or analogs thereof;
 - (d) a polynucleotide encoding a polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4 or fragments or analogs thereof;
 - (e) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4 or fragments or analogs thereof;
 - (f) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4 or fragments or analogs thereof;
 - (g) a polynucleotide comprising a sequence chosen from SEQ ID NO: 1 or 3 or fragments or analogs thereof;
 - (h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).
2. An isolated polynucleotide comprising a polynucleotide chosen from:
 - (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;

- (b) a polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;
- (c) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;
- (d) a polynucleotide encoding a polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;
- (e) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising a sequence chosen from: SEQ ID NO: 2 or 4;
- (f) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;
- (g) a polynucleotide comprising a sequence chosen from SEQ ID NO: 1 or 3;
- (h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).

3. The polynucleotide of claim 1, wherein said polynucleotide is DNA.

4. The polynucleotide of claim 2, wherein said polynucleotide is DNA.

5. The polynucleotide of claim 1, wherein said polynucleotide is RNA.

6. The polynucleotide of claim 2, wherein said polynucleotide is RNA.

7. An isolated polynucleotide that hybridizes under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises a sequence chosen from SEQ ID NO: 2 or 4 or fragments or analogs thereof.

8. The polynucleotide of claim 1 that hybridizes under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises a sequence chosen from SEQ ID NO: 2 or 4 or fragments or analogs thereof.

9. The polynucleotide of claim 2 that hybridizes under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises a sequence chosen from SEQ ID NO: 2 or 4.

10. The polynucleotide of claim 1 that hybridizes under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4 or fragments or analogs thereof.

11. The polynucleotide of claim 2 that hybridizes under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4.

12. A vector comprising the polynucleotide of claim 1, wherein said DNA is operably linked to an expression control region.
13. A vector comprising the polynucleotide of claim 2, wherein said DNA is operably linked to an expression control region.
14. A host cell transfected with the vector of claim 12.
15. A host cell transfected with the vector of claim 13.
16. A process for producing a polypeptide comprising culturing a host cell according to claim 14 under conditions suitable for expression of said polypeptide.
17. A process for producing a polypeptide comprising culturing a host cell according to claim 15 under condition suitable for expression of said polypeptide.
18. An isolated polypeptide comprising a polypeptide chosen from:
 - (a) a polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence comprising a sequence chosen from: SEQ ID NO: 2, 4 or fragments or analogs thereof;
 - (b) a polypeptide having at least 80% identity to a second polypeptide having an amino acid sequence comprising a sequence chosen from: SEQ ID NO: 2, 4 or fragments or analogs thereof;
 - (c) a polypeptide having at least 95% identity to a second polypeptide having an amino acid sequence comprising a sequence chosen from: SEQ ID NO: 2, 4 or fragments or analogs thereof;
 - (d) a polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof;

- (e) a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof;
- (f) an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof;
- (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- (h) the polypeptide of (a), (b), (c), (d), (e), or (f) wherein the secretory amino acid sequence is deleted.

19. An isolated polypeptide comprising a polypeptide chosen from:

- (a) a polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence comprising a sequence chosen from: SEQ ID NO: 2 or 4;
- (b) a polypeptide having at least 80% identity to a second polypeptide having an amino acid sequence comprising a sequence chosen from: SEQ ID NO: 2 or 4;
- (c) a polypeptide having at least 95% identity to a second polypeptide having an amino acid sequence comprising a sequence chosen from: SEQ ID NO: 2 or 4;
- (d) a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;
- (e) a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;
- (f) an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NO: 2 or 4;
- (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- (h) the polypeptide of (a), (b), (c), (d), (e), or (f) wherein the secretory amino acid sequence is deleted.

20. A chimeric polypeptide comprising two or more polypeptides having a sequence chosen from SEQ ID NO: 2, 4 or fragments or analogs thereof; provided that the polypeptides are linked as to form a chimeric polypeptide.
21. A chimeric polypeptide comprising two or more polypeptides having a sequence chosen from SEQ ID NO: 2 or 4 provided that the polypeptides are linked as to form a chimeric polypeptide.
22. A pharmaceutical composition comprising a polypeptide according to any one of claims 18 to 21 and a pharmaceutically acceptable carrier, diluent or adjuvant.
23. A method for prophylactic or therapeutic treatment of Moraxella infection in a host susceptible to Moraxella infection comprising administering to said host a prophylactic or therapeutic amount of a composition according to claim 22.
24. A method according to claim 23 wherein the host is a neonate, an infant or a child.
25. A method according to claim 23 wherein the host is an immunocompromised host.
26. A method according to claim 23 wherein the host is an adult.
27. A method for therapeutic or prophylactic treatment of otitis media, sinusitis, persistent cough, acute laryngitis, suppurative keratitis, conjunctivitis neonatorum, and invasive disease comprising administering to said host a therapeutic or prophylactic amount of a composition according to claim 22.
28. A method for diagnostic of Moraxella infection in a host susceptible to Moraxella infection comprising
 - (a) obtaining a biological sample from a host;

- (b) incubating an antibody or fragment thereof reactive with a polypeptide according to any one of claims 18 to 21 with the biological sample to form a mixture; and
- (c) detecting specifically bound antibody or bound fragment in the mixture which indicates the presence of Moraxella.

29. A method for the detection of antibody specific to a Moraxella antigen in a biological sample containing or suspected of containing said antibody comprising

- (a) obtaining a biological sample from a host;
- (b) incubating one or more polypeptides according to any one of claims 18 to 21 or fragments thereof with the biological sample to form a mixture; and
- (c) detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to Moraxella.

30. Use of the pharmaceutical composition according to claim 22 in the manufacture of a medicament for the prophylactic or therapeutic treatment of Moraxella infection.

31. Kit comprising a polypeptide according to any one of claims 18 to 21 for detection or diagnosis of Moraxella infection.

Figure 1 (SEQ ID NO: 1)

```

1 ATGACGGCCC ATAAAGATCG GTCAACCAAC CTCTCAAAAA TATGCTTAAA
51 ACATTGTTTT TTCACATCAA GTCTCATCGC CACATTGGCA ATGGGGTTGG
101 CGATGAGTGC TTGTAGTGAT GACGCCCAA AATCCCCTAT AATCAAACCT
151 GCTGATGATG GCATCATACT TAATAAAGAC AGCATCATGA CCGTCAAGAT
201 GTCCAAATAT CAGCCAAGTT TTGCCTTGA TGGTAAAATT ATCCCAGCCA
251 ATCAGACCCT ATTTAAATCTT GATACTGCTG TGATCGTTGA GCATATTTT
301 GTTGATGCAG GTGATGAGGT TTCCAAAGGC GATGCACTAC TTGGTTATTT
351 CACCCATTAA GAATCTTGC CCAGCGAAGT TACTACCTG CCTGCGCCAT
401 TTGATGGGGT GGTTCATCGT GTCTTGCCC ACACAGATCA GCACTATGAT
451 GCCAATACGC CATTAATTGA GATTCATGAT ATTTCTCAAT TAAAATTCAT
501 CAGCTATTG TCTTCTGCAC TGATGAATGA TACCAAATTG GGCGATGCGG
551 TAACTTTGG GGTTGATGGT ATTGCTCATG TTGGACAGAT TAGCCAAGTG
601 AATGTCAGTG AACAAAACCC CAAACTCATT GAAGTACATG TCATCATCGA
651 ACCCAATCCT GATGAAAAGC CCAAAGATCT GCTTGGGGCGG CGTGTGGTTG
701 GGCATATTGA TTATGGACAA ATCCAAGTTG GGGTCATGAT GCCCAGCAGC
751 GCTGTTTATG ACAGCGATTT GAATATCTT GCGTTAGATG GATTGATAA
801 GCCACCACAT AAGCCAGATG CTCCGATTGA TGGCTATGTT TGGGTCGTAA
851 AACAAAGACCA CCGACTGTCC CTGTCCTCTG TAAAAGTTT GGAATACCAT
901 CCCAAAATC AGCAATTGTT AGTGCAGGT ATCACCGAAG ACAGTCTTGT
951 TGCCACAGTG CCCTTACCAA AAGACGCACA TGATAAGCCA GTCAAAGTAT
1001 ACTAA

```

Figure 2 (SEQ ID NO: 2)

```

1 MTAHKDRSTN LSKICLKHF FTSSLIATLA MGLAMSACSD DRPKSPIIKP
51 ADDGIILNKG SIMTVKMSKY QPSFAFDGKI IPANQTLLNL DTAVIVEHIF
101 VDAGDEVSKG DALLGYFTHL ESLPSEVTTL PAPFDGVVHR VFAHTDQHYD
151 ANTPLIEIHD ISQLKFISYL SSALMNDTKL GDAVTFGVDG IAHVGQISQV
201 NVSEQNPKLI EVHVIIEPNP DEKPKDLLGR RVVGHIDYQQ IQVGVMMPS
251 AVYDSDLNIL ALDGFDFKPPH KPDAPIDGYV WVKQDHRLS LSPVKVLEYH
301 PKTQQFLVQG ITEDSLVATV PLPKDAHDKP VKVY*

```

Figure 3 (SEQ ID NO: 3)

```

1 ATGTATCAGC GCTTTATCAA TACCGCATTG GTTGCAGCTT TGGCGGTAAC
51 TATGGCAGGT TGTGGCACCA AAGCCATCAA GCCAACCGAA CGCAAGCCTG
101 CCAAATTGGT TAATATTCAAG ACGCCAGTCG CTGTATTAAC ACAGGTATCA
151 AGTATCCGCT TGGATCAAGG TCGATCTGGC TTTAGTCGTC GTAATACCAA
201 CCTAAGAAAG GATGTTATTG ATTTACAAAT TGACCCGTTG GCAGATGGTA
251 TGATTGCAGC AAGTCGCACT GGTATCGTCA GTGGTTACAT GGGTGAATCG
301 ATTGCTTGGC AATATAATGC TGAAGATGTG ATCACTGGCG GTGTCGGTAT
351 TGATGATCAA GGTAGTGTGG CGGTCAATTGG TACGCGTCA GGGAAATTAA
401 TTGCATTAGA TGCTCGACAC GGTGCAGCAC GCTGGGTAGT AGAATTGGCT
451 TCTTCTAGTT TGGCACCAAG ATTGATTAGT GGTGATAAAG TGATTGTCAT
501 CACTAACAGT GGTACGATTT TTGGATTGGA TATTAATAGT GGTGCGACAG
551 TTTGGCAGTA TGCCACTCAG GTACCAAATA CCAGTGTGCG TGGTATGGCA
601 AAGCCTTGG CGCTTGATGC TCGCACGGTA TTGATTGGTG GTGCTGATGG
651 GCGTATTTCAT GCACTAGATA CCATGACAGG TGCACCAGTG TGGACTCGCC
701 GTGTGGGACT GGCATGGGT TCTGGAGAAA TTGATCAGCT GCGTGTGATATT
751 GATGGGACAC CGACCGTCGT AGATCATTAT CTATACGCTG CCAGCTACAG
801 CGGACAATTAA GCTGGGTTTG ATATGACAAC AGGGCGTACC ATGTTTGTCA
851 GCGAGCTATC TAGCACCAAA AAGCTGACCA CTTTGGCTGA TGCTGTCATC
901 GGTAGTAGCA CTGATGGTGA TGTGGTTGCC TTTAACCGAA TGACTGGCGA
951 GAAGCTTGG GAAAATCATG ATCTAAAATA TCGTGGATTG ACCAATCCTG
1001 CAACCACATCGG CACTTATATT GCTGGTGGGG ATGCAGATGG TGTGGTACAT
1051 ATTTTAAATC ATCAAGGTCA AATTATCAGC CGAGCCAATA CCAAAGGTGC
1101 TTTGACCAAC TTAACGTGA TCAATAATCG CTTATATGCC CAATCAGCAG
1151 ATGGCGTTGT GACTGTTGG CAATTAA

```

Figure 4 (SEQ ID NO: 4)

```

1 MYQRFINTAL VAALAVTMAG CGTKAIKPTE RKPAKLVNIQ TPVALTQVS
51 SIRLDQGRSG FSRRNTNLRK DVIDLQIAPL ADGMIAASRS GIVSGYMGES
101 IAWQYNAEDV ITGGVGIDQ GSVAVIGTRS GKLIALDART GAARWVVELA
151 SSSLAPALIS GDKVIVITNS GTIFGLDINS GATVWQYATQ VPNTSVRGMA
201 KPLALDARTV LIGGADGRIH ALDTMTGAPV WTRRVGLAMG SGEIDQLRDI
251 DGTPTVVDHY LYAASYSGQL AGFDMTTGRT MFVSELSSTK KLTTLADAVI
301 GSSTDGDVVA FNRMTGEKLW ENHDLKYRGL TNPATIGTYI AVGDADGVVH
351 ILNHQGQIIS RANTKGALTN LTVINNRLYA QSADGVVTW QF*

```

SEQUENCE LISTING

<110> Shire Biochem Inc.

<120> MORAXELLA (BRANHAMELLA) CATARRHALIS ANTIGENS

<130> 74872-84

<150> US 60/298,403

<151> 2001-06-18

<150> US 60/330,095

<151> 2001-10-19

<160> 12

<170> PatentIn version 3.0

<210> 1

<211> 1005

<212> DNA

<213> Moraxella catarrhalis

<400> 1

atgacggccc	ataaaagatcg	gtcaaccaac	ctctcaaaaa	tatgcttaaa	acattgtttt	60
ttcacatcaa	gtctcatcgc	cacattggca	atggggttgg	cgatgagtgc	ttttagttagat	120
gaccgccccaa	aatcccctat	aatcaaacct	gtctatgtat	gcatactatact	taataaaagac	180
agcatcatga	ccgtcaagat	gtccaaatat	cagccaaatgtt	ttgccttga	tggtaaaatt	240
atcccagcca	atcagaccct	attaaatctt	gatactgctg	tgatcggtga	gcataatttt	300
gtttagatcg	gtttagatcg	ttccaaaggc	gatgcactac	ttggtttattt	caccatatta	360
aatcttgc	ccagcgaagt	tactaccctg	cctgcgccat	ttgatgggtt	ggttcatcgt	420
gtctttgccc	acacagatca	gcactatgtat	gccaatacgc	cattaattga	gattcatgat	480
atttctcaat	taaaattcat	cagctatttg	tcttctgcac	tgatgaatga	taccaaatttg	540
ggcgatgcgg	taactttgg	ggtttagatgt	attgctcatg	ttggacagat	tagccaagtg	600
aatgtcagtg	aacaaaaccc	caaactcatt	gaagtagatg	tcatcatcga	acccaatcct	660
gatggaaagc	ccaaagatct	gcttggcgg	cgtgtggttg	ggcatattga	ttatggacaa	720
atccaaagtgt	gggtcatgtat	gcccagcagc	gctgtttatg	acagcgattt	aatatctta	780
gcgttagatg	gatttgataa	gccaccacat	aagccagatg	ctccgattga	tggctatgtt	840
tgggtcgtaa	aacaagacca	ccgactgtcc	ctgtcccctg	taaaagttt	gaaataccat	900
cccaaaaactc	agcaattttt	agtgcaggt	atcaccgaag	acagtcttgt	tgccacagtg	960
cccttaccaa	aagacgcaca	tgataagcca	gtcaaagtat	actaa		1005

<210> 2

<211> 334

<212> PRT

<213> Moraxella catarrhalis

<400> 2

Met	Thr	Ala	His	Lys	Asp	Arg	Ser	Thr	Asn	Leu	Ser	Lys	Ile	Cys	Leu
1				5				10					15		

Lys	His	Cys	Phe	Phe	Thr	Ser	Ser	Leu	Ile	Ala	Thr	Leu	Ala	Met	Gly
			20				25					30			

Leu	Ala	Met	Ser	Ala	Cys	Ser	Asp	Asp	Arg	Pro	Lys	Ser	Pro	Ile	Ile
			35				40				45				

Lys	Pro	Ala	Asp	Asp	Gly	Ile	Ile	Leu	Asn	Lys	Asp	Ser	Ile	Met	Thr
			50			55				60					

Val Lys Met Ser Lys Tyr Gln Pro Ser Phe Ala Phe Asp Gly Lys Ile
 65 70 75 80
 Ile Pro Ala Asn Gln Thr Leu Leu Asn Leu Asp Thr Ala Val Ile Val
 85 90 95
 Glu His Ile Phe Val Asp Ala Gly Asp Glu Val Ser Lys Gly Asp Ala
 100 105 110
 Leu Leu Gly Tyr Phe Thr His Leu Glu Ser Leu Pro Ser Glu Val Thr
 115 120 125
 Thr Leu Pro Ala Pro Phe Asp Gly Val Val His Arg Val Phe Ala His
 130 135 140
 Thr Asp Gln His Tyr Asp Ala Asn Thr Pro Leu Ile Glu Ile His Asp
 145 150 155 160
 Ile Ser Gln Leu Lys Phe Ile Ser Tyr Leu Ser Ser Ala Leu Met Asn
 165 170 175
 Asp Thr Lys Leu Gly Asp Ala Val Thr Phe Gly Val Asp Gly Ile Ala
 180 185 190
 His Val Gly Gln Ile Ser Gln Val Asn Val Ser Glu Gln Asn Pro Lys
 195 200 205
 Leu Ile Glu Val His Val Ile Ile Glu Pro Asn Pro Asp Glu Lys Pro
 210 215 220
 Lys Asp Leu Leu Gly Arg Arg Val Val Gly His Ile Asp Tyr Gly Gln
 225 230 235 240
 Ile Gln Val Gly Val Met Met Pro Ser Ser Ala Val Tyr Asp Ser Asp
 245 250 255
 Leu Asn Ile Leu Ala Leu Asp Gly Phe Asp Lys Pro Pro His Lys Pro
 260 265 270
 Asp Ala Pro Ile Asp Gly Tyr Val Trp Val Val Lys Gln Asp His Arg
 275 280 285
 Leu Ser Leu Ser Pro Val Lys Val Leu Glu Tyr His Pro Lys Thr Gln
 290 295 300
 Gln Phe Leu Val Gln Gly Ile Thr Glu Asp Ser Leu Val Ala Thr Val
 305 310 315 320
 Pro Leu Pro Lys Asp Ala His Asp Lys Pro Val Lys Val Tyr
 325 330

<210> 3
 <211> 1179
 <212> DNA
 <213> Moraxella catarrhalis

<400> 3
 atgtatcgc gctttatcaa taccgcattt gttgcagctt tggcggttaac tatggcaggt 60
 tgtggcacca aagccatcaa gccaaccgaa cgcaagcctg ccaaatttgt taatattcag 120
 acgccagtcg ctgtattaaac acaggtatca agtatccgct tggatcaagg tcgatctggc 180
 tttagtcgtc gtaataccaa cctaagaaag gatgttattt atttacaat tgcaccgttg 240

gcagatggta	tgattgcagc	aagtgcgagt	ggtatcgta	gtggttacat	gggtgaatcg	300
attgcttggc	aatataatgc	tgaagatgt	atcaactggcg	gtgtcggtat	tgtatgatcaa	360
ggtagtgtgg	cggtcattgg	tacgcgtca	ggaaattaa	ttgcattaga	tgctcgcaca	420
ggtgcagcac	gctgggtagt	agaattggct	tcttctagtt	tggcaccagc	attgattagt	480
ggtgataaaag	tgattgtcat	cactaacagt	ggtacgattt	ttggatttgg	tattaatagt	540
ggtgcgacag	tttggcagta	tgccactcg	gtaccaaata	ccagtgtcg	ttgtatggca	600
aagccttgg	cgcttgatgc	tcgcacgta	ttgattggtg	gtgctgatgg	gcgtattcat	660
gcactagata	ccatgacagg	tgcaccagt	tggactcgcc	gtgtggact	ggcgtatgggt	720
tctggagaaa	ttgatcagct	gcgtgatatt	gatgggacac	cgaccgtcgt	agatcattat	780
ctatacgtcg	ccagctacag	cggacaatta	gctgggtttg	atatgacaac	agggcgtacc	840
atgttgtca	gcgagctatc	tagcacaaa	aagctgacca	ctttggctga	tgctgtcatc	900
ggtagtagca	ctgatggta	tgtggttgcc	tttaaccgaa	tgactggcga	gaagctttgg	960
gaaaatcatg	atctaaaata	tcgtggattt	accaatcctg	caaccatcg	cacttatatt	1020
gctgttgggg	atgcagatgg	tgtggtacat	attttaatc	atcaaggta	aattatcagc	1080
cgagccaata	ccaaagggtgc	tttgaccaac	ttaactgtga	tcaataatcg	cttatatgcc	1140
caatcagcag	atggcggtgt	gactgtttgg	caattttaa			1179

<210>	4															
<211>	392															
<212>	PRT															
<213>	Moraxella catarrhalis															
<400>	4															
Met	Tyr	Gln	Arg	Phe	Ile	Asn	Thr	Ala	Leu	Val	Ala	Ala	Leu	Ala	Val	
1				5				10				15				
Thr	Met	Ala	Gly	Cys	Gly	Thr	Lys	Ala	Ile	Lys	Pro	Thr	Glu	Arg	Lys	
							20		25				30			
Pro	Ala	Lys	Leu	Val	Asn	Ile	Gln	Thr	Pro	Val	Ala	Val	Leu	Thr	Gln	
					35			40				45				
Val	Ser	Ser	Ile	Arg	Leu	Asp	Gln	Gly	Arg	Ser	Gly	Phe	Ser	Arg	Arg	
					50			55				60				
Asn	Thr	Asn	Leu	Arg	Lys	Asp	Val	Ile	Asp	Leu	Gln	Ile	Ala	Pro	Leu	
65					70				75				80			
Ala	Asp	Gly	Met	Ile	Ala	Ala	Ser	Arg	Ser	Gly	Ile	Val	Ser	Gly	Tyr	
				85				90				95				
Met	Gly	Glu	Ser	Ile	Ala	Trp	Gln	Tyr	Asn	Ala	Glu	Asp	Val	Ile	Thr	
				100				105				110				
Gly	Gly	Val	Gly	Ile	Asp	Asp	Gln	Gly	Ser	Val	Ala	Val	Ile	Gly	Thr	
				115				120				125				
Arg	Ser	Gly	Lys	Leu	Ile	Ala	Leu	Asp	Ala	Arg	Thr	Gly	Ala	Ala	Arg	
				130				135			140					
Trp	Val	Val	Glu	Leu	Ala	Ser	Ser	Ser	Leu	Ala	Pro	Ala	Leu	Ile	Ser	
145				150					155			160				
Gly	Asp	Lys	Val	Ile	Val	Ile	Thr	Asn	Ser	Gly	Thr	Ile	Phe	Gly	Leu	
				165				170			175					
Asp	Ile	Asn	Ser	Gly	Ala	Thr	Val	Trp	Gln	Tyr	Ala	Thr	Gln	Val	Pro	
				180				185			190					
Asn	Thr	Ser	Val	Arg	Gly	Met	Ala	Lys	Pro	Leu	Ala	Leu	Asp	Ala	Arg	
				195				200			205					

Thr Val Leu Ile Gly Gly Ala Asp Gly Arg Ile His Ala Leu Asp Thr
 210 215 220

 Met Thr Gly Ala Pro Val Trp Thr Arg Arg Val Gly Leu Ala Met Gly
 225 230 235 240

 Ser Gly Glu Ile Asp Gln Leu Arg Asp Ile Asp Gly Thr Pro Thr Val
 245 250 255

 Val Asp His Tyr Leu Tyr Ala Ala Ser Tyr Ser Gly Gln Leu Ala Gly
 260 265 270

 Phe Asp Met Thr Thr Gly Arg Thr Met Phe Val Ser Glu Leu Ser Ser
 275 280 285

 Thr Lys Lys Leu Thr Thr Leu Ala Asp Ala Val Ile Gly Ser Ser Thr
 290 295 300

 Asp Gly Asp Val Val Ala Phe Asn Arg Met Thr Gly Glu Lys Leu Trp
 305 310 315 320

 Glu Asn His Asp Leu Lys Tyr Arg Gly Leu Thr Asn Pro Ala Thr Ile
 325 330 335

 Gly Thr Tyr Ile Ala Val Gly Asp Ala Asp Gly Val Val His Ile Leu
 340 345 350

 Asn His Gln Gly Gln Ile Ile Ser Arg Ala Asn Thr Lys Gly Ala Leu
 355 360 365

 Thr Asn Leu Thr Val Ile Asn Asn Arg Leu Tyr Ala Gln Ser Ala Asp
 370 375 380

 Gly Val Val Thr Val Trp Gln Phe
 385 390

<210> 5
 <211> 31
 <212> DNA
 <213> Artificial

 <220>
 <223> primer

 <400> 5
 taaggataca tatgacggcc cataaaagatc g 31

<210> 6
 <211> 36
 <212> DNA
 <213> Artificial

 <220>
 <223> primer

 <400> 6
 tatgctcgag gtatactttg actggcttat catgtg 36

<210> 7
<211> 29
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 7
gagtgcggat cctgatgacc gcccaaaat 29

<210> 8
<211> 36
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 8
tgttattaagc ttttagtata ctttgactgg cttatc 36

<210> 9
<211> 34
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 9
cggatattca tatgtatcag cgctttatca atac 34

<210> 10
<211> 31
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 10
atagatctcg agaaattgcc aaacagtcac a 31

<210> 11
<211> 33
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 11
actatgagat cttgggcacc aaagccatca agc 33

<210> 12
<211> 36

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 12

gattatgtcg acttaaaatt gccaaacagt cacaac

36